Product Datasheet

BGB116673

Catalog No. **BP-02260** · CAS **2736508-60-2** · Form **free base** · Physical state **other** · Color **Light yellow to green yellow** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
PROTACs; Btk; NF-κB	**Inflammation/Immunology; Cancer**

Molecular formula	$C_{47}H_{54}N_{12}O_4$
Molecular weight	**851.0097**

STRUCTURE



DESCRIPTION

BGB-16673 is an investigational BTK-targeting chimeric degradation activation compound (CDAC) active against both wild-type and mutant BTK.

BIOLOGICAL ACTIVITY

BTK-IN-29 (compound 14) is an inhibitor of Btk.

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 125 mg/mL

REFERENCES

[1]. Wang H, et al. BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models. Blood, 2024, 144: 5833.

[2]. Wu Y, et al. Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase-targeted protein degrader BGB-16673. Br J Pharmacol. 2024 Dec;181(24):4973-4987.

[3]. Hexiang Wang, et al. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use. WO2021219070A1. 2021-11-04.